clinical
During the Affimed (NASDAQ: NASDAQ:) second quarter 2024 earnings and corporate update call, the company highlighted significant clinical progress with their innate cell engagers, particularly in treating non-small cell lung cancer, Hodgkin lymphoma, and acute myeloid leukemia. The new CEO, Shawn Leland, emphasized the potential of these programs and the…
Affimed N.V. (NASDAQ: NASDAQ:), a clinical-stage biopharmaceutical company, has provided an update on its clinical and financial status during its Fourth Quarter and Full Year 2023 Earnings and Corporate Update Call. The company has achieved significant clinical milestones with its three key assets—AFM24, Acimtamig, and AFM28—and has implemented a major…
